Immunic Appoints Michael W. Bonney as Board Chair to Advance MS Treatment Development

Immunic, Inc. (IMUX) has recently appointed Michael "Mike" W. Bonney as Chair of its Board of Directors, a move anticipated to have significant implications for the company's future, particularly as it nears critical phases in its drug development process. Bonney’s extensive experience in the biopharmaceutical industry, especially in multiple sclerosis (MS), positions him as a key player in guiding Immunic towards its strategic goals. His background, which includes key leadership roles at Biogen Inc. and Cubist Pharmaceuticals, indicates a wealth of knowledge that could enhance Immunic's operational direction and board dynamics.

Strategic Leadership for Future Growth

Bonney’s appointment is set to take effect on May 16, 2026, and is seen as a strategic fit for Immunic as it focuses on progressing its lead candidate, vidofludimus calcium, through regulatory channels. This therapy holds promise for treating relapsing MS, a field in which Bonney has previously made a significant impact. His insights into the market dynamics of MS therapeutics could prove invaluable as Immunic prepares for the upcoming phase 3 ENSURE trials.

A Focused Vision for Neurological Disorders

Immunic’s CEO, Daniel Vitt, expresses confidence in Bonney’s ability to facilitate a successful transition into a commercial stage company, drawing on his past experiences in significant biopharmaceutical transitions. The Board’s composition, which will still include interim chair Simona Skerjanec, reflects a blend of continuity and new vision, crucial as Immunic advances its drug pipeline targeting not only MS but also other debilitating neurologic diseases.

Enhancing Immunic's Position in the Biotech Sector

Bonney has articulated the unique potential of vidofludimus calcium, which he describes as a therapy that combines neuroprotective and anti-inflammatory effects. This differentiation could provide Immunic with a competitive edge in a crowded market, positioning the company as a key innovator in MS treatment.

Immunic's commitment to advancing its drug therapies reflects its broader vision of not only addressing unmet medical needs but also reinforcing its presence in the biopharmaceutical landscape.